Welcome to independent research
It's easy to be our client. You won't get calls from our trading desk because we don't have one. You don't have to wonder if our research opinions are driven by our investment bankers because we don't have those, either. And you'll never, ever have to wonder if we are pumping a stock to bail our fund out of a bad position because we don't run a fund.
The biotech fund PMs who read our research tell us it's an easy read, despite the detail and volume we publish, because they don't have to always read between the lines to figure out the real story.
We're not your soup-to-nuts shop. We're concentrated and detailed, focusing on two or three dozen names out of a universe of 600 healthcare stocks and 250 development-stage biotech stocks. We closely follow each, providing you numerous research notes each time relevant information on the company arrives on our desk via press release or our own primary research efforts.
In 2006, we published nearly 300 notes on the companies in our coverage universe. At the end of each month, we give you a handy summary of the major events (great as a quick reference tool). We also use our monthly summary to debut new coverage or add value by disseminating important macro market or sector issues affecting your portfolio's value.
If you are going to outperform your peers, you need a competitive edge. We ensure BSR provides you value by enforcing a limit on the number of subscribers. If everyone knows what you know, your edge disappears. We also employ state-of-the-art document security and aggressive terms of use to help ensure our other clients do not dilute your investment by sharing our research with others.
There are hundreds of research providers out there, but BSR's independence, coverage concentration, and limited distribution gives our clients the edge they need to outperform.
If you'd like to sample our research, you can access selected samples of past research here.
The biotech fund PMs who read our research tell us it's an easy read, despite the detail and volume we publish, because they don't have to always read between the lines to figure out the real story.
We're not your soup-to-nuts shop. We're concentrated and detailed, focusing on two or three dozen names out of a universe of 600 healthcare stocks and 250 development-stage biotech stocks. We closely follow each, providing you numerous research notes each time relevant information on the company arrives on our desk via press release or our own primary research efforts.
In 2006, we published nearly 300 notes on the companies in our coverage universe. At the end of each month, we give you a handy summary of the major events (great as a quick reference tool). We also use our monthly summary to debut new coverage or add value by disseminating important macro market or sector issues affecting your portfolio's value.
If you are going to outperform your peers, you need a competitive edge. We ensure BSR provides you value by enforcing a limit on the number of subscribers. If everyone knows what you know, your edge disappears. We also employ state-of-the-art document security and aggressive terms of use to help ensure our other clients do not dilute your investment by sharing our research with others.
There are hundreds of research providers out there, but BSR's independence, coverage concentration, and limited distribution gives our clients the edge they need to outperform.
If you'd like to sample our research, you can access selected samples of past research here.
Our core research offering
The best research in the world does you no good if the cost blows your budget. We've committed to a low-cost research model. In fact, many of our clients tell us they can't believe how professional and useful our research is for the price. Sure, you can pay six figures for biotech research, but why would you want to?
Full subscriptions come in either six-month or twelve-month plans. You receive access to all our current research plus access to archives going back to 2001. Click here or on the 'i' at the upper right of this page for pricing information and to become client immediately. We require payment in advance of access, but we will do soft money invoicing for renewals. If you are not satisfied, we will refund the pro-rated amount left on your subscription according to our terms and conditions.
For the skeptics, we offer a two-month subscription. You only have access to the current research plus 45 days of archives, though. Introductory subscriptions do not have access to the archives. Introductory subscriptions can only be renewed to six-month or twelve-month full subscriptions. Click here or on the 'i' at the upper right of this page for pricing information and to become client immediately.
Full subscriptions come in either six-month or twelve-month plans. You receive access to all our current research plus access to archives going back to 2001. Click here or on the 'i' at the upper right of this page for pricing information and to become client immediately. We require payment in advance of access, but we will do soft money invoicing for renewals. If you are not satisfied, we will refund the pro-rated amount left on your subscription according to our terms and conditions.
For the skeptics, we offer a two-month subscription. You only have access to the current research plus 45 days of archives, though. Introductory subscriptions do not have access to the archives. Introductory subscriptions can only be renewed to six-month or twelve-month full subscriptions. Click here or on the 'i' at the upper right of this page for pricing information and to become client immediately.